FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast Cancer-Reference-Cited by-同舟云学术

FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast Cancer

Published:2018-02-07 Issue:13 Volume:24 Page:2999-3004
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Shah Anand,Bloomquist Erik,Tang Shenghui,Fu Wentao,Bi Youwei,Liu Qi,Yu Jingyu,Zhao Ping,Palmby Todd R.,Goldberg Kirsten B.,Chang C.J. George,Patel Paresma,Alebachew Elleni,Tilley Amy,Pierce William F.,Ibrahim Amna,Blumenthal Gideon M.,Sridhara Rajeshwari,Beaver Julia A.,Pazdur Richard

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 86 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Abemaciclib increases the risk of venous thromboembolism in breast cancer: Integrate meta-analysis, pharmacovigilance database analysis, and in vitro validation;Cancer Treatment Reviews;2024-11

2. Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment;Drug Resistance Updates;2024-09

3. CDK4/6 inhibitors plus endocrine therapy vs. placebo plus endocrine therapy for HR+/HER2- advanced breast cancer: a phase III RCTs based meta-analysis;BMC Cancer;2024-08-21

4. A review of trilaciclib, a first-in-class cyclin-dependent kinase 4/6 inhibitor, for the management of metastatic small-cell lung cancer;Medicinal Chemistry Research;2024-07-26

5. A patent review of small molecule CDK4/6 inhibitors in the treatment of cancer: 2020–present;Expert Opinion on Therapeutic Patents;2024-07-17